- Home
- PSNL vs PMVP Comparison
PSNL vs PMVP Comparison
Compare PSNL & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | PMVP |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 79.5M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PSNL | PMVP |
|---|---|---|
| Price | $6.09 | $1.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $12.20 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 339.0K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,648,000.00 | N/A |
| Revenue This Year | $15.47 | N/A |
| Revenue Next Year | $39.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.97 | $0.83 |
| 52 Week High | $11.50 | $1.88 |
Technical Indicators
Market Signals| Indicator | PSNL | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 34.67 | 47.32 |
| Support Level | $4.65 | $1.26 |
| Resistance Level | $9.64 | $1.50 |
| Average True Range (ATR) | 0.50 | 0.07 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 8.88 | 38.33 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.